Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study

Sofia Genta(Ente Ospedaliero Cantonale), Luca Ceriani(St Thomas' Hospital), Luciano Cascione(Institute of Oncology Research), Teresa Ruberto(Ente Ospedaliero Cantonale), Maria Cristina Pirosa(Institute of Oncology Research), Darius Juškevičius(University of Basel), Guido Ghilardi(Hospital of the University of Pennsylvania), Fabiana Esposito(Ente Ospedaliero Cantonale), Sämi Schär(Swiss Group For Clinical Cancer Research), Stefanie Hayoz(Swiss Group For Clinical Cancer Research), Luca Giovanella(Ente Ospedaliero Cantonale), Christoph Mamot(Kantonsspital Aarau), Stefan Dirnhofer(University of Basel), Emanuele Zucca(Ente Ospedaliero Cantonale), Alexandar Tzankov(University Hospital of Basel), Lisa Milan(Ente Ospedaliero Cantonale)
Cancers
February 17, 2022
10.3390/cancers14041018
Cited by 13

Related Papers

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|390
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
|Nature Medicine|2022|308
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
|Nature Medicine|2024|254